This review discusses the evidence supporting the use of an intranasal formulation combining the antihistamine azelastine hydrochloride with the corticosteroid fluticasone propionate (Dymista®) for the management of moderate to severe allergic rhinitis and rhino-conjunctivitis in adults and adolescents.
It summarises the key clinical trial outcomes as well as real-world studies on Dymista effectiveness, across different allergic rhinitis subpopulations. Finally, a treatment algorithm is presented, highlighting the position of Dymista in the allergic rhinitis treatment pathway. This review was created with unconditional funding from Viatris.
Download PDF